Literature DB >> 1966550

Protection against gram-negative bacteremia in neutropenic mice with recombinant granulocyte-macrophage colony-stimulating factor.

L E Bermudez1, J C Martinelli, R Gascon, M Wu, L S Young.   

Abstract

Granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates production of neutrophils in bone marrow and may decrease the incidence of infection during neutropenia. We evaluated the protective role of recombinant GM-CSF against Pseudomonas aeruginosa challenge in neutropenic mice. CD-1 mice treated with cyclophosphamide on days 1 and 2 of the experiment were given GM-CSF (1, 2, or 4 micrograms/day) starting at day 4 of the experiment according to the following protocol: 1) 1 microgram of GM-CSF 2 hr and 24 hr after challenge; 2) 1 microgram 24 hr before challenge, 2 hr and 24 hr after challenge; 3) 2 micrograms injected 24 hr before and 2 hr after challenge; 4) 2 micrograms given 24 hr before and 2 micrograms given 2 hr and 24 hr after challenge; 5) 4 micrograms administered 2 hr and 24 hr after challenge; and 6) saline and bovine albumin controls. The number of blood neutrophils by days 4 and 5 was similar for GM-CSF-treated and untreated animals. Survival was significantly greater in animals given 2 micrograms of GM-CSF at 24 hr before and at 2 hr and 24 hr after challenge with Pseudomonas. Neutrophils and splenic macrophages obtained from GM-CSF-treated mice (2 micrograms/animal) produced significantly greater amounts of O2- (204 +/- 36 nmoles/10(5) cells) than controls (21 +/- 10 nmoles/10(5) cells). Additionally, neutrophils and macrophages from GM-CSF-treated mice killed significantly more bacteria (P. aeruginosa) in vitro and had a greater number of C3b and Fc receptors (78 +/- 12% and 89 +/- 8%) than did cells obtained from control animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1966550     DOI: 10.1016/1043-4666(90)90030-w

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

1.  Colony-Stimulating Factors in the Therapeutic Approach to Sepsis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

2.  Influence of cystic fibrosis transmembrane conductance regulator on gene expression in response to Pseudomonas aeruginosa infection of human bronchial epithelial cells.

Authors:  Nina Reiniger; Jeffrey K Ichikawa; Gerald B Pier
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

3.  Selective early production of CCL20, or macrophage inflammatory protein 3alpha, by human mast cells in response to Pseudomonas aeruginosa.

Authors:  Tong-Jun Lin; Lauren H Maher; Kaede Gomi; Jeffrey D McCurdy; Rafael Garduno; Jean S Marshall
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

4.  Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin) stimulates neutrophils and tissue macrophages and induces an effective non-specific response against Mycobacterium avium in mice.

Authors:  L E Bermudez; M Petrofsky; P Stevens
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

5.  Intravenous delivery of granulocyte-macrophage colony stimulating factor impairs survival in lipopolysaccharide-induced sepsis.

Authors:  Jörg Krebs; Alexander Hillenbrand; Charalambos Tsagogiorgas; Christian Patry; Burkhard Tönshoff; Benito Yard; Grietje Beck; Neysan Rafat
Journal:  PLoS One       Date:  2019-06-20       Impact factor: 3.240

Review 6.  A Review of GM-CSF Therapy in Sepsis.

Authors:  Brittany Mathias; Benjamin E Szpila; Frederick A Moore; Philip A Efron; Lyle L Moldawer
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.